Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...

Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.

Weber said it is the right time to appoint a successor given "our competitive growth outlook, new product launches expected ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...